

Satralizumab

Cat. No.:	HY-P99112
CAS No.:	1535963-91-7
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research ^{[1][2]} .									
IC₅₀ & Target	IL-6									
In Vivo	<p>Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattus norvegicus^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Rattus norvegicus (forty, male, 10-week-old, four equal groups)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>120 mg</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneously, once every 2 weeks, for 4 weeks</td> </tr> <tr> <td>Result:</td> <td>Prevented dTAA (descending thoracic aorta aneurysm) formation and progression.</td> </tr> </table>		Animal Model:	Rattus norvegicus (forty, male, 10-week-old, four equal groups) ^[1]	Dosage:	120 mg	Administration:	Subcutaneously, once every 2 weeks, for 4 weeks	Result:	Prevented dTAA (descending thoracic aorta aneurysm) formation and progression.
Animal Model:	Rattus norvegicus (forty, male, 10-week-old, four equal groups) ^[1]									
Dosage:	120 mg									
Administration:	Subcutaneously, once every 2 weeks, for 4 weeks									
Result:	Prevented dTAA (descending thoracic aorta aneurysm) formation and progression.									

REFERENCES

- [1]. Heydari AH, et al. Satralizumab, Novel Interleukine-6 Inhibitor for Preventing Descending Thoracic Aorta Aneurysm Development. Cardiovasc Drugs Ther. 2021 Nov 26.
- [2]. Duchow A, et al. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegener Dis Manag. 2021 Feb;11(1):49-59.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA